



(51) International Patent Classification:

C07D 401/04 (2006.01) C07D 401/06 (2006.01)
C07D 471/04 (2006.01) C07D 401/14 (2006.01)
C07D 487/04 (2006.01) A61K 31/4166 (2006.01)
C07D 247/02 (2006.01) A61K 31/4427 (2006.01)

(21) International Application Number:

PCT/IB2014/065175

(22) International Filing Date:

9 October 2014 (09.10.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

3207/MUM/2013 10 October 2013 (10.10.2013) IN

(71) Applicant: GLENMARK PHARMACEUTICALS S.A.
[CH/CH]; Chemin de la Combeta 5, CH-2300 La Chaux-de-Fonds (CH).

(72) Inventors: DAS, Sanjib; 148 Muktaram Babu Street, West Bengal, Kolkata 700007 (IN). THOMAS, Abraham; Flat No. 5, 11th Floor, Building No. A-6, Millennium Towers, Sector 9, Sanpada, Maharashtra, Navi Mumbai 400705 (IN). KHAIRATKAR-JOSHI, Neelima; 101, Devprayag CHS, Bhakti Mandir Rd, Hari Niwas, Panchpakhadi, Maharashtra, Thane (W) 400602 (IN). SHAH, Daisy, Man-


ish; Padmashree Bldg, 1st Floor, Flat no 4, Anant Patil Marg, Gokhale Road, Dadar (W), Maharashtra, Mumbai 400028 (IN). **BAJPAI, Malini**; 47/9 Kabir Marg (Clay Square), Uttar Pradesh, Lucknow 226001 (IN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: SUBSTITUTED DIHYDRO-BENZIMIDAZOLE COMPOUNDS AS ROR GAMMA MODULATORS



(I)

(57) Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as modulator of retinoid-related orphan receptor gamma t (RORyt). These compounds prevent, inhibit, or suppress the action of RORyt and are therefore useful in the treatment of RORyt mediated disease, disorder, syndrome or condition such as pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, neurodegenerative diseases or cancer.

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*